Stevanato Group S.p.A. 2023 Annual Review Highlights

Stevanato Group S.p.A. (NYSE: STVN), a global leader in integrated solutions for the pharmaceutical, biotech, and life sciences industries, delivered a strong performance in fiscal year 2023. Robust demand for its high-value solutions and strategic investments in capacity and innovation fueled this success.

Business Overview: Stevanato Group operates through two main business segments: Biopharmaceutical and Diagnostic Solutions (BDS) and Engineering. The BDS segment, which provides drug containment solutions (such as vials, cartridges, and syringes) and drug delivery systems, served as the primary growth driver. It benefited from increased demand for advanced primary packaging and integrated solutions, particularly for biologics and vaccines. The Engineering segment, which supplies high-precision production equipment, also contributed positively by supporting the global expansion of pharmaceutical manufacturing capabilities.

Financial Performance: For fiscal year 2023, Stevanato Group reported revenue of approximately €1.1 billion, a 15% increase year-over-year. This growth was largely organic, with the BDS segment's revenue jumping 17% to €950 million, driven by its high-value solutions portfolio. Adjusted EBITDA climbed 20% to €300 million from the previous year, demonstrating improved operational efficiency and a favorable product mix. Net profit for the year rose 25% to €150 million, resulting in earnings per share (EPS) of €0.57. The company also expanded its gross margin by 150 basis points to 32%, reflecting strong pricing power and effective cost management.

Management Discussion (MD&A Highlights): Key achievements in 2023 included the successful launch of advanced pre-fillable syringe platforms designed for sensitive biologics, securing several multi-year supply agreements with major pharmaceutical clients, and completing significant capacity expansion projects in both Europe and North America to meet growing demand. The company also made progress in its sustainability initiatives, reducing its carbon footprint. While persistent inflationary pressures on raw materials and energy costs posed challenges, the company partially offset these through pricing adjustments and efficiency gains. Geopolitical uncertainties and supply chain disruptions for certain components also required proactive management, though their impact was mitigated.

Financial Health: Stevanato Group maintains a solid financial position. As of December 31, 2023, the company reported cash and cash equivalents of €250 million. Net debt stood at €180 million, resulting in a healthy net debt-to-Adjusted EBITDA ratio of 0.6x, which indicates strong leverage management. Operating cash flow generation was robust at €220 million, providing ample liquidity for ongoing operations, capital expenditures, and potential strategic investments. The company's strong balance sheet supports its growth ambitions without significant reliance on external financing.

Risk Factors: Investors should be aware of several key risks:

• Dependence on the highly regulated pharmaceutical industry: Changes in regulations or drug development cycles could impact demand.
• Intense competition: Both established players and new entrants could exert pressure on pricing and market share.
• Supply chain vulnerabilities: Particularly for specialized raw materials like pharmaceutical-grade glass, these remain a concern.
• Currency fluctuations: These pose potential risks given the company's global operations.
• Integration of future acquisitions: Successfully integrating any future acquisitions could present challenges.
• Intellectual property protection and product liability: These are inherent risks in the industry.

Competitive Position: Stevanato Group differentiates itself through its integrated offering, providing not just components but complete solutions from drug containment to delivery devices and the machinery to produce them. Its strong research and development (R&D) capabilities and focus on high-value, technologically advanced products (e.g., sterile, ready-to-use vials and syringes) position it favorably against competitors. The company's global manufacturing footprint and long-standing relationships with leading pharmaceutical companies further solidify its market position as a trusted partner for critical biopharmaceutical solutions.

Future Outlook: Looking ahead, Stevanato Group's strategy focuses on three pillars: innovation in high-value solutions, particularly for biologics and gene therapies; global capacity expansion to support customer growth; and operational excellence to drive efficiency and profitability. The company plans to invest approximately €180-200 million in capital expenditures in 2024 to further expand its manufacturing capabilities and R&D. For fiscal year 2024, Stevanato Group projects revenue growth of 10-12% and continued margin expansion, driven by sustained demand for its advanced solutions and a strong order backlog. The long-term vision is to be the preferred partner for biopharmaceutical innovation, leveraging its expertise to enable the safe and effective delivery of life-saving medicines.